•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced it will host an investor call on Monday, May 4, 2026 at 8:30 a.m. ET / 5:30 a.m. PT to share topline results from the VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC).
The company also said the call will be available via webcast through the Investors section of Mirum’s corporate website, with an archived webcast available for replay.
Mirum Pharmaceuticals (NASDAQ: MIRM) is a rare disease company with a global footprint of approved products and a pipeline of investigational medicines.
The company’s commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX).
Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).
Investor Contact: Andrew McKibben, ir@mirumpharma.com
Media Contact: Meredith Kiernan, media@mirumpharma.com
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
